
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Ling-Hua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George Muller, Peter Schafer, David Stirling, Angus G. Dalgleish, J. Blake BartlettVolume:
69
Année:
2005
Langue:
english
DOI:
10.1016/j.mvr.2005.01.002
Fichier:
PDF, 1.10 MB
english, 2005